# Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia

> **NCT00079313** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 7 (actual)

## Conditions studied

- Chronic Myelomonocytic Leukemia
- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT00079313
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01-14
- **Primary completion:** 2006-12-30
- **Final completion:** 2010-10-25
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00079313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00079313, "Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00079313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*